Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience

BACKGROUND: Anaemia is common in haemodialysis (HD) patients and associated with significant morbidity and mortality. Intravenous (IV) iron combined with erythropoiesis-stimulating agents (ESA) is the mainstay treatment of anaemia in these patients. The comparative efficacy and risk of adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales: Jesus-Silva, Jorge A., Lamplugh, Archie, Dhada, Sameera, Burton, James O., Bhandari, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271492/
https://www.ncbi.nlm.nih.gov/pubmed/32493240
http://dx.doi.org/10.1186/s12882-020-01866-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271492/
https://www.ncbi.nlm.nih.gov/pubmed/32493240
http://dx.doi.org/10.1186/s12882-020-01866-x

Ejemplares similares